Supporting the growth and development of MDMA-assisted psychotherapy practitioners and sites
The MDMA Therapy Training Program offers in-depth training into the practice of MDMA-Assisted Psychotherapy, with curriculum based on decades of clinical experience. Trainees learn the theoretical approach of the modality, developed from the fundamental notion that every person has within them an incredible source of wisdom and an innate ability to heal.
The MDMA Therapy Training Program provides the training and supervision required to qualify practitioners to deliver MDMA-Assisted Psychotherapy in approved clinical settings. As of Summer 2019, the MDMA Therapy Training Program has enrolled over 500 clinicians and delivered trainings in the United States, United Kingdom, Canada, the Netherlands, and Israel.
The MDMA Therapy Training Program enrolls compassionate and experienced clinicians who are committed to health and well-being. The program is currently accepting applications for mental health practitioners interested in learning the modality of MDMA-Assisted Psychotherapy.
MDMA-Assisted Psychotherapy Treatment Manual
Want to learn more about MDMA-Assisted Psychotherapy?
The 5-part training program is required for all MDMA-assisted therapy practitioners working on a MAPS protocol.
- 14 hours
- 7 Days
- 3+ Days
- 1 Day
The online course outlines chemistry and history of MDMA, common reactions, possible mechanisms of action, and study design. The online course was developed out of content from the Treatment Manual, study protocols, and scientific literature on the subject.
Therapy video review and live dialogue with Senior MDMA-assisted Psychotherapy Researchers, covers topics in the Treatment Manual. Trainees are taught how to conduct study sessions, provide non-directive therapy, and adhere to treatment protocol.
MAPS PBC is developing a protocol that would provide trainees with the opportunity to shadow alongside a senior MDMA therapist during an MDMA therapy session, in the spirit of apprenticeship. Additionally, the protocol would provide an opportunity for trainees to receive MDMA-assisted psychotherapy, if they choose to volunteer and are eligible. The experiential opportunity in psychedelic therapy training has proven invaluable according to previous trainees.
Therapy Teams from a given site gather to conduct role play didactic training. Role play scenarios are provided, and each trainee gets a chance to play the role of provider, participant, and observer. Total time: approximately 6 hours. The role plays will be video and audio recorded so that recording may be reviewed by a Supervisor.
Supervision and Evaluation
Trainees receive in-depth video review and clinical supervision during the treatment of their first participant receiving MDMA- assisted psychotherapy. Therapy video recordings are rated for adherence to the treatment method. Supervision is provided by Senior MDMA-assisted Psychotherapy Researchers. Timely feedback is given to trainees to maximize learning and enhance the quality of treatment. All therapy sessions for that participant must be audio and video recorded so that recordings may be viewed by a Supervision. Supervisors evaluate trainees based on adherence criteria, observation of therapy videos, and participation in training modules. A final evaluation is provided in the form of a narrative summary from the Supervisor. Trainees who have satisfied all the training requirements will be granted a certificate of completion. Until MDMA is approved as medicine by the regulatory authorities all practice will be in a limited clinical trial setting.
Tuition and Scholarships
Tuition information for the 2020 training year will be available in the coming months.
If you would like to support MDMA Therapy Training opportunities for people of color, please consider donating to this effort. Your donation is tax deductible and will help to build equity and inclusion for this important new healing modality.
Additional scholarship programs are under development.
In January 2019, just as Phase 3 trials began, MAPS PBC submitted an application to the US FDA Expanded Access program. If approved, Expanded Access would allow additional sites in the United States and US Territories to meet the requirements to provide MDMA-assisted psychotherapy for PTSD to eligible patients under a MAPS protocol.
Opportunities to participate on a MDMA-assisted psychotherapy protocol are expected to grow, in the United States and internationally. Due to the nature of clinical research and the regulatory approval process, it is difficult to predict the timing and outcome of protocol approvals. Eligible candidates are encouraged to apply and monitor the Connect Portal and MDMA Therapy Training Program Email Newsletter for updates.
MAPS PBC is currently accepting Site Questionnaires from sites in the United States and US Territories that are interested in being screened for initial eligibility to participate on a future MDMA-assisted psychotherapy protocol, pending approval.The growth of this modality is likely to happen gradually over the next few years. Due to the incredible interest in this modality, MAPS PBC may not be able to respond to all applicants at this time. Applications will be held until opportunities to increase the number of sites grow. Sites will be contacted for clarification on their Site Questionnaire responses as needed. At the time of review, applicants will be notified of their site’s initial eligibility status.
The MDMA Therapy Training Program is currently accepting Practitioner Training Applications from qualified applicants who would like to begin their training in the MDMA Therapy Training Program. Applications are reviewed on an ongoing basis, as they are received; applicants will be notified of their application status and will be contacted if needed for clarification on their application responses. The MDMA Therapy Training Program is a pre-requisite to working on a MAPS MDMA-Assisted Psychotherapy protocol; qualified practitioners who are enrolled in or have graduated from the MDMA Therapy Training Program will be considered for participation in future protocols, pending approval.
Due to the unpredictable nature of clinical research, we understand that many qualified practitioners may wish to wait until regulatory approval is granted, and opportunities to deliver MDMA-Assisted Psychotherapy are confirmed, before investing in their training with the MDMA Therapy Training Program. Please stay tuned to the Connect Portal and MDMA Therapy Training Program Email Newsletter where we will share updates on protocol status, training announcements, and other news related to MDMA-assisted psychotherapy. Thank you for your interest in healing, growth, and learning!
Code of Ethics
The MAPS MDMA Therapy Training Program is committed to providing quality and comprehensive training and supervision to support therapy providers in delivering ethical care within a MAPS MDMA-assisted psychotherapy protocol. As an organization, we take seriously our obligation to participant safety and to reflecting internally to promote ethical growth in our programs. In service to this commitment, the MDMA Therapy Training Program has established the MAPS MDMA-Assisted Psychotherapy Code of Ethics. The Code will remain a living document to grow and adapt with the ongoing integration of feedback and evolution of needs over time.
In the process of researching and drafting the Code of Ethics, the MDMA Therapy Training Program has been grateful to draw on collective wisdom within both psychotherapeutic and psychedelic fields. We wish to acknowledge input offered by our reviewers, as well as the work of many organizations and individuals to develop existing ethical guidelines.
Cedar Barstow, M.Ed., C.H.T.
Marca Cassity, BSN, LMFT
Karen M. Cooper, M.A., RN
Leia Friedman, M.S.
Ismail Lourido Ali, JD
Annie Mithoefer, BSN
Michael Mithoefer, M.D.
Angella Okawa, LMFT
Marcela Ot’alora, LPC
Bruce Poulter, RN
Dominic A. Sisti, Ph.D.
Kylea Taylor, M.S., LMFT
Verena Wieloch, LPCA, LCAS
and the generous contributions
of many others.